An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease

Leuven

Adelaide

Halle

Szekszárd

Cheektowaga

New York

Chevy Chase

Charlottesville

Richmond

Charlotte

Elkin

Atlanta

Decatur

Macon

Jacksonville

Winter Park

Miami

Birmingham

Germantown

Louisville

Troy

Ann Arbor

Milwaukee

Rochester

Kuala Lumpur

Tel Aviv

Topeka

Baton Rouge

Tyler

San Antonio

Lafayette

Littleton

Thornton

San Diego

San Francisco

Portland

Hamden

Edmonton

Saskatoon

Prague

Seoul